DPPA-based therapeutic liposome nanoparticle, and preparation method and application thereof

Abstract

The invention discloses a DPPA-based therapeutic liposome nanoparticle, which comprises a main drug and DPPA coupled with the main drug or wrapping the main drug, and the main drug is selected from at least one of drugs acting on tumor cells or target genes, proteins, DNA or RNA. According to the nanoparticles prepared based on DPPA, by means of the biological activity of the DPPA component, the nanoparticles prepared based on DPPA have the anti-angiogenesis and tumor inhibition effects besides the tumor effect of the main drug, and synergistic treatment and multiple regulation and control are achieved by combining the main drug. The DPPA belongs to a substance existing in an organism, so that the nanoparticles prepared on the basis of the DPPA have good in-vivo stability, small toxic and side effects and high safety. In addition, due to the anti-tumor characteristic of the DPPA component, the dosage of the entrapment substance can be reduced, so that the toxic and side effects possibly caused by the entrapment substance are further reduced.

Description

technical field [0001] The invention relates to the technical field of biomedicine, more specifically, to a DPPA-based therapeutic liposome nanoparticle and its preparation method and application. Background technique [0002] One of the common tumor treatment methods in the prior art is chemotherapeutic drug treatment, which acts on different links of tumor cell growth and reproduction through chemotherapeutic drugs to inhibit or kill various tumors. However, it can also kill normal cells while killing tumor cells, thus causing adverse reactions, including bone marrow suppression, heart damage, etc., that is, it has a defect of lack of targeting. [0003] For this reason, antibody-conjugated drug therapy methods and RNA interference-based therapy methods have also been developed in the prior art, both of which have a certain degree of targeting, and have advantages brought about by targeting compared with chemotherapy drug therapy. Among them, antibody-drug conjugates (ADC...

AI Technical Summary

Problems solved by technology

Compared with traditional chemotherapeutic drugs, antibody-drug conjugates can reduce or avoid drug damage to normal tissues, but they also have major defects: when the linker of antibody-drug conjugates is unstable, it is easy to cause systemic exposure of the drug, It can bind to normal tissues expressing the same antibody, resulting in off-target effects; and antibody-conjugated drugs are expensive, and the range of applicable populations is limited

However, the treatment methods based on nanoparticles loaded with therapeutic substances in the prior art still have shortcomings, that is, the nanocarriers in the nanoparticles only act as targeted delivery, and cannot use components other than the therapeutic substances loaded to play a therapeutic role.

Moreover, the therapeutic substances that nanocarriers can carry are limited, so it is often difficult to achieve multiple regulatory effects when using nano-delivery systems to treat related diseases

Take liposomal doxorubicin, the only nano-drug currently on the market, as an example. Through the superior tumor-targeting performance of nano-carriers, it can effectively reduce its systemic side effects, but its carrier only plays a delivery role and cannot further improve the treatment of tumors. Effect

Images